OnabotulinumtoxinA in chronic migraine: is the response dose dependent?

Overview of attention for article published in BMC Neurology, June 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 9 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 3 publications that cite this research output.

3

The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.

Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study

Article in Cephalalgia Reports (January 2024)

A UTILIZAÇÃO DA TOXINA BOTULÍNICA DO TIPO A PARA TRATAMENTO DA ENXAQUECA CRÔNICA: Uma revisão de literatura

Article in Revista Saúde dos Vales (November 2023)

The Development of Psychiatric Illness and Chemoprophylaxis of Botulinum Toxin in Migraine: A Narrative Review

Article in Cureus (December 2022)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.